Painful diabetic neuropathy: An update

Annals of Neurosciences

Volumn 18, Issue 4, 2011, Pages 168-175

  Kaur, Sharonjeet ^a   Pandhi, Promila ^a   Dutta, Pinaki ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Drugs; Painful diabetic neuropathy; Pathophysiology; Treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CAPSAICIN; CARBAMAZEPINE; DESIPRAMINE; FRUCTOSE; GABAPENTIN; GAMMA LINOLENIC ACID; HEMOGLOBIN A1C; IMIPRAMINE; LAMOTRIGINE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXCARBAZEPINE; OXYGEN; PLACEBO; PREGABALIN; PROTEIN KINASE C BETA INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SORBITOL; THIOCTIC ACID; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADRENERGIC SYSTEM; AGITATION; ARTICLE; ATAXIA; BLURRED VISION; BURNING SENSATION; COMORBIDITY; CONFUSION; CONSTIPATION; DIABETIC NEUROPATHY; DIPLOPIA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; FATIGUE; GLYCEMIC CONTROL; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERBARIC OXYGEN; HYPERGLYCEMIA; IMMUNOTHERAPY; LEUKOPENIA; LONG TERM POTENTIATION; NAUSEA; NEUROPATHY; NYSTAGMUS; ORTHOSTATIC HYPERTENSION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PREVALENCE; RASH; RHINITIS; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TREMOR; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 80052881413     PISSN: 09727531     EISSN: 09763260     Source Type: Journal    
DOI: 10.5214/ans.0972.7531.1118409     Document Type: Article

References (60)

1. Holzer SE, Camerota A, Martens L, et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 1998; 20: 169-181.
2. Boulton AJM and Malik RA. Diabetic Neuropathy. Medical Clinics of North America. 1998; 82: 909-929.
3. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998; 15: 508-514.
4. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-134.
5. Veves A, Manes C, Murray HJ, et al. Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care 1993; 16: 1187-1189.
6. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-128.
7. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26: 1790-1795.
8. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
9. DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-588.
10. Cameron NE and Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Res 1994; 10: 189-224
11. Bhadada SK, Sahay RK, Jyotsna VP, et al. Diabetic Neuropathy: Current Concepts. Journal of Indian Academy of Clinical Medicine. 2001; 2: 304-318.
12. Vinik AI, Kong X, Megerian JT, et al. Diabetic nerve conduction abnormalities in the primary care setting. Diabetes Technol Ther 2006; 8: 654-662
13. Armstrong DG, lavery LA, Vela SA, et al. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. Arch Intern Med 1998; 76: 68-71.
14. Maser RE, Laudadio C, Lenhard MJ, et al. A cross-sectional study comparing two quantitative sensory testing devices in individuals with diabetes. Diabetes Care 1997; 20: 179-181.
15. Rodriguez M, Trinajstic E, Munoz P. The tactile circumferential discriminator: an instrument for detecting patients at risk of foot ulceration. Diabetes Care 1997; 20: 1799.
16. Vileikyte L, Hutchings G, Hollis S, et al. The tactile circumferential discriminator. A new, simple screening device to identify diabetic patients at risk of foot ulceration. Diabetes Care 1997; 20: 623-626.
17. Dyck PJ. Quantitating severity of neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, et al. editors. Peripheral neuropathy, 3rd ed. Philadelphia: WB Saunders; 1993. 686-697.
18. Dyck PJ, Karnes J, OBrien PC, et al. Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology 1986; 36: 1300-1308.
19. Baron R. Peripheral neuropathic pain: From mechanisms to symptoms. Clin J Pain 2000; 16: S12-S20.
20. Scadding JW. Development of ongoing activity, mechanosensitivity, and adrenaline sensitivity in severed peripheral nerve axons. Exp Neurol 1981; 73: 345-364.
21. Tsigos C, Reed P, Weinkove C, et al. Plasma norepinephrine in sensory diabetic polyneuropathy. Diabetes Care 1993; 16: 722-727.
22. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: A review. Diabet Med 2003; 20: 88-98.
23. Sindrup SH, Otto M, Finnerup NB, et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96: 399-409
24. Max MB, Culnane M, Schafer SC, et al. Amitryptiline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589.
25. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful diabetic polyneuropathy: A randomized, controlled trial. Neurology 2003; 60: 1284-1289.
26. Raskin J, Pritchett JL, Wang F, et al. A doubleblind, multicenter trial comparing duloxetine with placebo in the treatment of diabetic peripheral neuropathic pain [abstract]. Diabetes 2005; 54: A126.
27. Kaur H, 100 D, Bhansali A, et al. A comparative trial to evaluate Amitryptyline and Duloxetine in painful diabetic neuropathy. Diabetes Care 2011, doi: 10.2337/ dc10-1793
28. Kochar DK, Jain N, Agarwal RP, et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes: a randomized placebo controlled study. Acta Neurol Scand 2002; 106: 248-252.
29. Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004; 97: 33-38.
30. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004; 110: 628-638.
31. Rosenberg JM, Harrell C, Risitic H, et al. The effect of gabapentine on neuropathic pain. Clin J Pain 1997; 13: 251-255.
32. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain 2007; 128: 169-179.
33. Jose VM, Bhansali A, Hota D, et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet. Med 2007; 24: 377-383
34. The capsaicin study group. Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double-blind, vehicle controlled study. Arch Intern Med 1991; 151: 2225-2229.
35. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: A doubleblind placebo controlled crossover study. Diabetes Care 2002; 25: 1699-1703.
36. McCleane GJ. Topical doxepin hydrochloride reduces neuropathic pain: a randomized, double blind, placebo controlled study. Pain Clin 1999; 12: 47-50.
37. Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complication. 2006; 20(1): 34-39.
38. Oskarsson P, ljunggren J-G, Lins P-E. Efficacy and safety of mexilitine in the treatment of painful diabetic neuropathy. The mexilitetine study group. Diabetes Care 1997. 20; 1594-1597.
39. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324-1334
40. Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-78
41. Harati Y, Gooch C, Swenson M, et al. Double blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846.
42. Cohen KL and Susanne H. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987; 147: 1442-14444.
43. Abuaisha BB, Constanzi JB, Boulton AJM. Acupuncture for the treatment of chronic painful diabetic neuropathy: A longterm study. Diabetes Res Clin Pract 1998; 39: 115-121.
44. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and post herpetic neuralgia. Neurology 1997; 48: 1212-1218.
45. Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trials. Anesthesiology 2002; 96: 1053-1061.
46. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46 (Suppl. z2): S82-S89.
47. Bril V. Status of current clinical trials in diabetic polyneuropathy. Can J Neurol Sci 2001; 28: 191-198.
48. Mizisin AP, Steinhardt RC, O'Brien JS, et al. TX14(A), a prosapos in derived peptide, reverses established nerve disorders in streptozotocin diabetic rats and prevents them in galactose-fed rats. J Neuropathol Exp Neurol 2001; 60: 953-960.
49. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 2000; 284: 2215-2221.
50. Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001; 107: 1215-1218.
51. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083-1092.
52. Keen H, Paxan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linoleic acid. Diabetes Care. 1993; 16: 8-15.
53. Vinik A, Bril V, Kempler P, et al., for the MBBQ Study. Treatment of symptomatic diabetic peripheral neuropathy with protein kinase CB inhibitor ruboxistaurin mesylate during a 1-year randomized, placebocontrolled, doubleblind clinical trial. Clin Therapeut 2005; 27: 1164-1180
54. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995; 52: 1053-1061.
55. Barada A, Reljanovic M, Milicevic Z, et al. Proximal diabetic neuropathy: response to immunotherapy [abstract]. Diabetes 1999; 48 (Suppl 1): A148.
56. Bloomgarden ZT. Diabetic Neuropathy. Daibetes Care 2008; 31: 616-621.
57. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicentre randomized doubleblind placebocontrolled trial (ALADIN II). Free Radic Res 1999; 31: 171-179.
58. Ametov AS, Barinov A, Dyck PJ, et al. SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alphalipoic acid: The SYDNEY trial. Diabetes Care 2003; 26: 770-776.
59. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352(9145): 1978-1981.
60. Bril V, England J, Franklin GM, et al. Evidencebased guideline: Treatment of painful diabetic neuropathy. e-Pub ahead of print on April 11, 2011, at www.neurology.org.